Inês Caldeira Brás, Luísa V. Lopes, Tiago Fleming Outeiro November 16, 2018

Abstract

Parkinson’s disease and other synucleinopathies are characterized by the accumulation of aggregated α‐synuclein in intracellular proteinaceous inclusions. The progressive nature of synucleinopathies seems to be related to the cell‐to‐cell spreading of α‐synuclein pathology, and several possible mechanisms have been put forward to explain this phenomenon.… Read More...

Marina Picillo, Karlo J. Lizarraga, Erik L. Friesen, Hien Chau, Ming Zhang, Christine Sato, Grace Rooke, Renato P. Munhoz, Ekaterina Rogaeva, Paul E. Fraser, Suneil K. Kalia, Lorraine V. Kalia November 16, 2018

Abstract

Background: SNCA mutations cause autosomal dominant parkinsonism and inform our understanding of the molecular underpinnings of synucleinopathies. The most recently identified mutation, p.Ala53Glu (A53E), has only been observed in Finland. The objectives of this study were to examine clinical, genetic, epigenetic, and biochemical features of the first family outside Finland with A53E.… Read More...

Manuel Delgado‐Alvarado, Rosalía Dacosta‐Aguayo, Irene Navalpotro‐Gómez, Belén Gago, Ana Gorostidi, Haritz Jiménez‐Urbieta, Ana Quiroga‐Varela, Javier Ruiz‐Martínez, Alberto Bergareche, María C. Rodríguez‐Oroz November 16, 2018

ABSTRACT

Background: There is a need for biomarkers of dementia in PD.

Objectives: To determine if the levels of the main CSF proteins and their ratios are associated with deterioration in cognition and progression to dementia in the short to mid term.… Read More...

Yue Xing, Abdul Sapuan, Rob A. Dineen, Dorothee P. Auer November 16, 2018

Abstract

Background: Neuromelanin is a pigment with strong iron‐chelating properties preferentially found in dopaminergic neurons of the substantia nigra pars compacta (SNpc). Parkinson’s disease is characterized by pronounced, MRI‐detectable neuromelanin loss, but the neuroprotective or neurotoxic role of neuromelanin remains debated.… Read More...

Roxanne Lofredi, Wolf‐Julian Neumann, Christof Brücke, Julius Huebl, Joachim K. Krauss, Gerd‐Helge Schneider, Andrea A. Kühn November 16, 2018

ABSTRACT

Background: Exaggerated beta power has been discussed as a disease‐specific biomarker for Parkinson’s disease (PD) and has recently been suggested to rely on prolonged bursts of subthalamic beta synchronization.

Objective: In this study, we test whether prolonged bursts are disease specific for beta activity in PD by comparison to oscillatory activity in dystonia.… Read More...

Andoird App
Loading...